356 related articles for article (PubMed ID: 24614714)
1. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
[TBL] [Abstract][Full Text] [Related]
2. Regulation of cellular therapies: the Australian perspective.
Wall DM; Prince HM
Cytotherapy; 2003; 5(4):284-8. PubMed ID: 12944233
[TBL] [Abstract][Full Text] [Related]
3. Regulation of cellular therapy in Australia.
Trickett AE; Wall DM
Pathology; 2011 Oct; 43(6):627-34. PubMed ID: 21897330
[TBL] [Abstract][Full Text] [Related]
4. Regulation Policy for Cell and Tissue Therapies in Australia.
Sturm M
Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
[TBL] [Abstract][Full Text] [Related]
5. [Update on regulatory framework and certification process].
Legrand D
Transfus Clin Biol; 2008 Nov; 15(5):193-6. PubMed ID: 18930686
[TBL] [Abstract][Full Text] [Related]
6. Transposition of the Blood Directive into national law--the perspective of Portugal.
Gonçalves MH; Muon MC; Gonçalves Jd
Transfus Clin Biol; 2005 Feb; 12(1):18-20. PubMed ID: 15814287
[TBL] [Abstract][Full Text] [Related]
7. GMP in blood collection and processing.
Wagstaff W
Vox Sang; 1998; 74 Suppl 2():513-21. PubMed ID: 9704492
[TBL] [Abstract][Full Text] [Related]
8. The quest for quality blood banking program in the new millennium the American way.
Kim DU
Int J Hematol; 2002 Aug; 76 Suppl 2():258-62. PubMed ID: 12430934
[TBL] [Abstract][Full Text] [Related]
9. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
[TBL] [Abstract][Full Text] [Related]
10. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
[TBL] [Abstract][Full Text] [Related]
11. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2015 May; 80(99):29841-906. PubMed ID: 26003966
[TBL] [Abstract][Full Text] [Related]
12. Blood transfusion in Europe: basic principles for initial and continuous training in transfusion medicine: an approach to an European harmonisation.
Mueller MM; Seifried E
Transfus Clin Biol; 2006 Nov; 13(5):282-5; quiz 286-9. PubMed ID: 17196864
[TBL] [Abstract][Full Text] [Related]
13. Current regulatory issues in cell and tissue therapy.
Burger SR
Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
[TBL] [Abstract][Full Text] [Related]
14. Bacteriology laboratories and musculoskeletal tissue banks in Australia.
Varettas K
ANZ J Surg; 2012 Nov; 82(11):775-9. PubMed ID: 22882601
[TBL] [Abstract][Full Text] [Related]
15. "Eurocode International Blood Labeling System" enables unique identification of all biological products from human origin in accordance with the European Directive 2004/23/EC.
Knels R; Mönig HJ; Wittmann G; von Versen R; Pruss A
Cell Tissue Bank; 2010 Nov; 11(4):345-52. PubMed ID: 20563859
[TBL] [Abstract][Full Text] [Related]
16. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
[TBL] [Abstract][Full Text] [Related]
17. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
Abbasalizadeh S; Baharvand H
Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
[TBL] [Abstract][Full Text] [Related]
18. Voluntary accreditation of cellular therapies: Foundation for the Accreditation of Cellular Therapy (FACT).
Warkentin PI;
Cytotherapy; 2003; 5(4):299-305. PubMed ID: 12944235
[TBL] [Abstract][Full Text] [Related]
19. The implementation of tissue banking experiences for setting up a cGMP cell manufacturing facility.
Arjmand B; Emami-Razavi SH; Larijani B; Norouzi-Javidan A; Aghayan HR
Cell Tissue Bank; 2012 Dec; 13(4):587-96. PubMed ID: 21870140
[TBL] [Abstract][Full Text] [Related]
20. The applicability of cGMP to cord blood cell banking.
Zuck TF
J Hematother; 1996 Apr; 5(2):135-7. PubMed ID: 8723789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
